Carolina Arancibia

• Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

  West NR. et al, (2017), Nat Med, 23, 579 - 589

• Th1 and Innate Lymphoid Cells accumulate in Primary Sclerosing Cholangitis-associated Inflammatory Bowel Disease.

  Gwela A. et al, (2017), J Crohns Colitis

• RORγt inhibitors suppress T(H)17 responses in inflammatory arthritis and inflammatory bowel disease.

  de Wit J. et al, (2016), J Allergy Clin Immunol, 137, 960 - 963

• Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.

  Paterson AM. et al, (2015), J Exp Med, 212, 1603 - 1621

• Co‐Administration of Co‐Stimulatory Moieties

  Latchman YE. and Arancibia CV., (2012), Vaccinology Principles and Practice, 375 - 392

• IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease.

  Geremia A. et al, (2011), J Exp Med, 208, 1127 - 1133

• Auto-antibody production and glomerulonephritis in congenic Slamf1-/- and Slamf2-/- [B6.129] but not in Slamf1-/- and Slamf2-/- [BALB/c.129] mice.

  Keszei M. et al, (2011), Int Immunol, 23, 149 - 158

• Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis.

  Izcue A. et al, (2008), Immunity, 28, 559 - 570

• A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism.

  Coombes JL. et al, (2007), J Exp Med, 204, 1757 - 1764

• A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites.

  Arancibia-Cárcamo CV. et al, (2004), Eur J Immunol, 34, 471 - 480

• Gene delivery to the corneal endothelium.

  George AJ. et al, (2000), Am J Respir Crit Care Med, 162, S194 - S200

• A method for determining the cytoprotective effect of catalase in transiently transfected cell lines and in corneal tissue.

  Oral HB. et al, (1999), Anal Biochem, 267, 196 - 202

• A CIITA dominant negative mutant

  (1998), Expert Opinion on Therapeutic Patents, 8, 1759 - 1761

• Lipid-mediated enhancement of transfection by a nonviral integrin-targeting vector.

  Hart SL. et al, (1998), Hum Gene Ther, 9, 575 - 585

• Lipoadenofection-mediated gene delivery to the corneal endothelium: prospects for modulating graft rejection.

  Arancibia-Cárcamo CV. et al, (1998), Transplantation, 65, 62 - 67

• The role of minor histocompatibility alloantigens in penetrating keratoplasty.

  Arancibia C. et al, Dev Ophthalmol

Recent Publications

• Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

  West NR. et al, (2017), Nat Med, 23, 579 - 589
• Th1 and Innate Lymphoid Cells accumulate in Primary Sclerosing Cholangitis-associated Inflammatory Bowel Disease.

  Gwela A. et al, (2017), J Crohns Colitis
• RORγt inhibitors suppress T(H)17 responses in inflammatory arthritis and inflammatory bowel disease.

  de Wit J. et al, (2016), J Allergy Clin Immunol, 137, 960 - 963
• Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.

  Paterson AM. et al, (2015), J Exp Med, 212, 1603 - 1621
• Co‐Administration of Co‐Stimulatory Moieties

  Latchman YE. and Arancibia CV., (2012), Vaccinology Principles and Practice, 375 - 392